BIOCRYST (BCRX) director Steven Frank receives 1,285-share stock retainer grant

Rhea-AI Filing Summary

Frank Steven reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC director Steven Frank received an equity grant of 1,285 shares of Common Stock on February 27, 2026. The shares were issued in lieu of 100% of his quarterly cash board member retainer of $11,250, reflecting a stock-based compensation choice rather than a market purchase. Following this award, he directly owns 18,903 shares of the company’s common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Frank Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,285	$8.75	$11K

Holdings After Transaction: Common Stock — 18,903 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frank Steven

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		1,285(1)	A	$8.75	18,903	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

	/s/ Alane P. Barnes, by power of attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BIOCRYST (BCRX) director Steven Frank report?

Director Steven Frank reported receiving 1,285 shares of BIOCRYST Common Stock. The shares were granted as compensation, issued instead of his quarterly cash board retainer, and not bought on the open market. This increased his direct holdings to 18,903 shares.

Was the BIOCRYST (BCRX) Form 4 transaction a stock purchase or a grant?

The Form 4 transaction was a stock grant, not a market purchase. Steven Frank received 1,285 Common Stock shares as payment in stock for his $11,250 quarterly board retainer, reflecting equity-based director compensation rather than an open-market trading decision.

How many BIOCRYST (BCRX) shares does Steven Frank own after this Form 4?

After this reported grant, Steven Frank directly owns 18,903 shares of BIOCRYST Common Stock. The Form 4 shows his holdings increased when he received 1,285 shares in lieu of his quarterly cash board retainer of $11,250.

What was the implied price per share in Steven Frank’s BIOCRYST (BCRX) stock grant?

The grant used an implied price of $8.75 per share. BIOCRYST issued 1,285 Common Stock shares to Steven Frank in lieu of a $11,250 quarterly board member cash retainer, as disclosed in the Form 4 and related footnote.

Why did BIOCRYST (BCRX) issue shares to Steven Frank instead of paying cash?

BIOCRYST issued shares in lieu of Steven Frank’s cash board retainer. The footnote explains the 1,285 Common Stock shares replaced 100% of his $11,250 quarterly cash Board Member retainer, indicating an equity-based form of director compensation for that period.

Does the BIOCRYST (BCRX) Form 4 indicate indirect ownership or another entity for this grant?

The Form 4 shows the shares as directly owned by Steven Frank. The transaction is coded as direct ownership with no footnote transferring voting or investment power to another entity, so the 1,285 granted shares are attributed to him personally.